February 7, 2023 03:57 PM ESTUpdated February 8, 09:12 AM
Pharma
Marketing

Re­searchers pan phar­ma DTC ad­ver­tis­ing for high spend­ing on low-val­ue drugs — JA­MA re­port

Beth Snyder Bulik

Senior Editor

New re­search is look­ing to con­nect the dots be­tween di­rect-to-con­sumer (DTC) ad­ver­tis­ing and low­er clin­i­cal ben­e­fits or ther­a­peu­tic val­ue. A

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times